Moreover, an ongoing phase II trial is testing the combination of olaparib and cediranib or AZD6738 (ATR inhibitor) for the treatment of advanced or metastatic germline BRCA-mutated breast cancer (NCT04090567). Here, ATR is linked to breast cancer.